X
PharmEasy

₹6.50

mrf 0.00%
05 Mar 2026

Listing Status: Active

Connect: •••
•••• ••••
•••
Key Metrics of PharmEasy
  • Market Cap11,071.12 Cr.
  • Total Equity Funding$688M in 11 rounds
  • Latest Funding Round$193M, Conventional Debt Sep 16, 2025
  • Post Money Valuation
  • Annual Revenue₹75 Cr
  • EBITDA₹2 Cr
  • EBITDA Margin2.48%
  • Net Profit₹0 Cr
  • Net Profit Margin0.41%
About the Company

Provider of an online pharmacy and healthcare platforms. It offers a wide range of pharmaceutical products, healthcare and wellness items,...

Loading...
Price on BSE Volume

Funding Rounds

Total Rounds: 11 Pharmeasy

S.No. Date Round Name Amount TTM Revenue Investors & Facilitators
1. Sep 16, 2025 Conventional Debt $193M $7.1M
Inst: 360 One, Bennett, Coleman
2. May 10, 2022 Series F - $42.0M
Inst: GSV
3. Feb 21, 2022 Series F - $41.7M
Inst: GSV
4. Jun 28, 2021 Series F $300M $23.0M
Inst: Temasek, TPG, Prosus, Think Investments, Kotak Investment Advisors, B Capital
5. Feb 24, 2021 Series D $66.4M $16.8M
Inst: Temasek, Caisse de depot et placement du Quebec, Timesgroup, TPG, Lightrock
6. Nov 26, 2019 Series D $220M -
Inst: Temasek, Bessemer Venture Partners, Orios Venture Partners, Eight Roads Ventures, F-Prime Capital, Fundamentum, Avendus, Caisse de depot et placement du Quebec, KB Global Holdings, KB Investment, Think Investments, LGT Group
Angel: Nandan, Sanjeev, Harsh, Hardik
7. Sep 26, 2018 Series C $50M -
Inst: Fundamentum, Eight Roads Ventures, F-Prime Capital, Bessemer Venture Partners, Ascent Health & Wellness Solutions, Think Investments
Angel: Bina, Anuj, Manju, Ramakant
Facil: Avendus
8. Sep 11, 2018 Venture Debt $5.5M -
Inst: Innoven Capital
9. Feb 28, 2018 Series C $30M -
Inst: Bessemer Venture Partners, Orios Venture Partners, Trifecta Capital, Ascent Health & Wellness Solutions, MEMG Family Office, JM Financial
10. Mar 25, 2017 Series B $17M -
Inst: Bessemer Venture Partners, Orios Venture Partners, Trifecta Capital, Ascent Health & Wellness Solutions
Angel: Shivanand, Laxmi, Kedar
11. 2015 Series A $5M -
Inst: Bessemer Venture Partners, Orios Venture Partners, Aarin Capital, Astarc Ventures, Ascent Health & Wellness Solutions, MediBuddy

Financial Statements

Revenue - INR (Cr)

Net Profit/Loss - INR (Cr)

Select a year from the tabs

FY 24-25
FY 23-24
FY 22-23
FY 21-22
FY 20-21
FY 19-20
Detailed Income StatementFY 24-25 (in Cr)
75.5
75.2
Total profit before prior period items, exceptional items, extraordinary items and tax 0.3
Total profit before extraordinary items and tax 0.3
Total profit before tax 0.3
0
Total profit (loss) for period from continuing operations 0.3
Profit (loss) from discontinuing operations before tax 0
Tax expense of discontinuing operations 0
Total profit (loss) for period before minority interest 0.3
Profit (loss) of minority interest 0
Total profit (loss) for period 0.3
Basic earning per equity share 0.0
Diluted earnings per equity share 0.0
Detailed Balance SheetFY 24-25 (in Cr)
35.7
35.7
Detailed Cash Flow StatementFY 24-25 (in Cr)
Cash flow from operating activities 1.4
Net cash from / (used in) operating activities 1.4
Cash flow from investing activities 1.1
Net cash from / (used in) investing activities 1.1
Cash flow from financing activities (4.1)
Net cash from / (used) in financing activities (4.1)
Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes (1.5)
Net increase / (decrease) in cash and cash equivalents (1.5)
Cash and cash equivalents at the beginning of the year 8.2
Cash and cash equivalents at the end of the year 6.7
Detailed Income StatementFY 23-24 (in Cr)
103.8
104.0
Total profit before prior period items, exceptional items, extraordinary items and tax (0.2)
Total profit before extraordinary items and tax (0.2)
Total profit before tax (0.2)
0
Total profit (loss) for period from continuing operations (0.2)
Profit (loss) from discontinuing operations before tax 0
Tax expense of discontinuing operations 0
Total profit (loss) for period before minority interest (0.2)
Profit (loss) of minority interest 0
Total profit (loss) for period (0.2)
Basic earning per equity share (0.0)
Diluted earnings per equity share (0.0)
Detailed Balance SheetFY 23-24 (in Cr)
33.2
33.2
Detailed Cash Flow StatementFY 23-24 (in Cr)
Cash flow from operating activities 6.4
Net cash from / (used in) operating activities 6.4
Cash flow from investing activities (0.1)
Net cash from / (used in) investing activities (0.1)
Cash flow from financing activities (5.4)
Net cash from / (used) in financing activities (5.4)
Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes 0.9
Net increase / (decrease) in cash and cash equivalents 0.9
Cash and cash equivalents at the beginning of the year 7.3
Cash and cash equivalents at the end of the year 8.2
Detailed Income StatementFY 22-23 (in Cr)
258.3
259.0
Total profit before prior period items, exceptional items, extraordinary items and tax (0.8)
Total profit before extraordinary items and tax (0.8)
Total profit before tax (0.8)
0
Total profit (loss) for period from continuing operations (0.8)
Profit (loss) from discontinuing operations before tax 0
Tax expense of discontinuing operations 0
Total profit (loss) for period before minority interest (0.8)
Profit (loss) of minority interest 0
Total profit (loss) for period (0.8)
Basic earning per equity share (0.0)
Diluted earnings per equity share (0.0)
Detailed Balance SheetFY 22-23 (in Cr)
51.9
51.9
Detailed Cash Flow StatementFY 22-23 (in Cr)
Cash flow from operating activities 9.5
Net cash from / (used in) operating activities 9.5
Cash flow from investing activities (0.7)
Net cash from / (used in) investing activities (0.7)
Cash flow from financing activities (11.1)
Net cash from / (used) in financing activities (11.1)
Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes (2.3)
Net increase / (decrease) in cash and cash equivalents (2.3)
Cash and cash equivalents at the beginning of the year 9.5
Cash and cash equivalents at the end of the year 7.3
Detailed Income StatementFY 21-22 (in Cr)
327.9
319.3
Total profit before prior period items, exceptional items, extraordinary items and tax 8.6
Total profit before extraordinary items and tax 8.6
Total profit before tax 8.6
0.3
Total profit (loss) for period from continuing operations 8.3
Profit (loss) from discontinuing operations before tax (13.7)
Tax expense of discontinuing operations 0
Total profit (loss) from discontinuing operation after tax (13.7)
Total profit (loss) for period before minority interest (5.4)
Profit (loss) of minority interest 0
Total profit (loss) for period (5.4)
Basic earning per equity share (0.0)
Diluted earnings per equity share (0.0)
Detailed Balance SheetFY 21-22 (in Cr)
88.2
88.2
Detailed Cash Flow StatementFY 21-22 (in Cr)
Cash flow from operating activities 21.6
Net cash from / (used in) operating activities 21.6
Cash flow from investing activities 0.3
Net cash from / (used in) investing activities 0.3
Cash flow from financing activities 29.0
Net cash from / (used) in financing activities 29.0
Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes 50.9
Net increase / (decrease) in cash and cash equivalents 50.9
Cash and cash equivalents at the beginning of the year 1.9
Cash and cash equivalents at the end of the year 9.5
Detailed Income StatementFY 20-21 (in Cr)
119.0
98.3
Total profit before prior period items, exceptional items, extraordinary items and tax 20.7
Total profit before extraordinary items and tax 20.7
Total profit before tax 20.7
(0.1)
Total profit (loss) for period from continuing operations 20.8
Profit (loss) from discontinuing operations before tax (19.8)
Tax expense of discontinuing operations 0
Total profit (loss) from discontinuing operation after tax (19.8)
Total profit (loss) for period before minority interest 1.0
Profit (loss) of minority interest 0
Total profit (loss) for period 1.0
Basic earning per equity share 0.0
Diluted earnings per equity share 0.0
Detailed Balance SheetFY 20-21 (in Cr)
38.8
38.8
Detailed Cash Flow StatementFY 20-21 (in Cr)
Cash flow from operating activities 0.5
Net cash from / (used in) operating activities 0.5
Cash flow from investing activities (0.1)
Net cash from / (used in) investing activities (0.1)
Cash flow from financing activities 0
Net cash from / (used) in financing activities 0
Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes 0.5
Net increase / (decrease) in cash and cash equivalents 0.5
Cash and cash equivalents at the beginning of the year 1.4
Cash and cash equivalents at the end of the year 1.9
Detailed Income StatementFY 19-20 (in Cr)
181.7
194.1
Total profit before prior period items, exceptional items, extraordinary items and tax (12.5)
Total profit before extraordinary items and tax (12.5)
Total profit before tax (12.5)
(0.1)
Total profit (loss) for period from continuing operations (12.3)
Total profit (loss) for period before minority interest (12.3)
Total profit (loss) for period (12.3)
Basic earning per equity share 0
Diluted earnings per equity share 0
Detailed Balance SheetFY 19-20 (in Cr)
33.1
33.1
Detailed Cash Flow StatementFY 19-20 (in Cr)
Cash flow from operating activities 11.7
Net cash from / (used in) operating activities 11.7
Cash flow from investing activities (1.6)
Net cash from / (used in) investing activities (1.6)
Cash flow from financing activities (4.1)
Net cash from / (used) in financing activities (4.1)
Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes 5.9
Net increase / (decrease) in cash and cash equivalents 5.9
Cash and cash equivalents at the beginning of the year 0
Cash and cash equivalents at the end of the year 5.9

Top Competitors

Similar companies to Pharmeasy

Tata 1mg

1mg.com

MedPlus

medplusmart.com

SastaSundar

sastasundar.com

API Holdings

apiholdings.in

Truemeds

truemeds.in

Netmeds

netmeds.com

Latest News

Updates on Pharmeasy
Need help? Chat with us! WhatsApp